Literature DB >> 9806639

The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes.

S J Gobin1, A Peijnenburg, M van Eggermond, M van Zutphen, R van den Berg, P J van den Elsen.   

Abstract

In type III bare lymphocyte syndrome (BLS) patients, defects in the RFX protein complex result in a lack of MHC class II and reduced MHC class I cell surface expression. Using type III BLS cell lines, we demonstrate that the RFX subunits RFX5 and RFXAP are crucial for constitutive and CIITA-induced MHC class I and beta2m transactivation. Similar to MHC class II, the promoters of MHC class I and beta2m contain an S-X-Y region of which the X1 box is crucial for constitutive and CIITA-induced MHC class I and beta2m transactivation. Thus, the RFX complex is part of a regulatory pathway linking the transactivation of MHC class I and II and their accessory genes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9806639     DOI: 10.1016/s1074-7613(00)80636-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  32 in total

Review 1.  The bare lymphocyte syndrome: molecular clues to the transcriptional regulation of major histocompatibility complex class II genes.

Authors:  A DeSandro; U M Nagarajan; J M Boss
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  Expression of nonclassical MHC class Ib genes: comparison of regulatory elements.

Authors:  T Kevin Howcroft; Dinah S Singer
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Potential regulatory sequences in the untranslated regions of the baboon MHC class Ib gene, Paan-AG, more closely resemble those in the human MHC class Ia genes than those in the class Ib gene, HLA-G.

Authors:  Daudi K Langat; Pedro J Morales; Asgerally T Fazleabas; Joan S Hunt
Journal:  Immunogenetics       Date:  2004-11-17       Impact factor: 2.846

5.  NLRP2 is a suppressor of NF-ƙB signaling and HLA-C expression in human trophoblasts†,‡.

Authors:  Tamara Tilburgs; Torsten B Meissner; Leonardo M R Ferreira; Arend Mulder; Kiran Musunuru; Junqiang Ye; Jack L Strominger
Journal:  Biol Reprod       Date:  2017-04-01       Impact factor: 4.285

Review 6.  Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance.

Authors:  Saptha Vijayan; Tabasum Sidiq; Suhail Yousuf; Peter J van den Elsen; Koichi S Kobayashi
Journal:  Immunogenetics       Date:  2019-01-31       Impact factor: 2.846

Review 7.  What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules?

Authors:  Alan Belicha-Villanueva; Jennifer Blickwedehl; Sarah McEvoy; Michelle Golding; Sandra O Gollnick; Naveen Bangia
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

8.  Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer.

Authors:  Hannah V Siddle; Alexandre Kreiss; Cesar Tovar; Chun Kit Yuen; Yuanyuan Cheng; Katherine Belov; Kate Swift; Anne-Maree Pearse; Rodrigo Hamede; Menna E Jones; Karsten Skjødt; Gregory M Woods; Jim Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

9.  Tumor necrosis factor α-induced hypoxia-inducible factor 1α-β-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling.

Authors:  Sadashib Ghosh; Arkoprovo Paul; Ellora Sen
Journal:  Mol Cell Biol       Date:  2013-05-13       Impact factor: 4.272

10.  A whole genome Bayesian scan for adaptive genetic divergence in West African cattle.

Authors:  Mathieu Gautier; Laurence Flori; Andrea Riebler; Florence Jaffrézic; Denis Laloé; Ivo Gut; Katayoun Moazami-Goudarzi; Jean-Louis Foulley
Journal:  BMC Genomics       Date:  2009-11-21       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.